FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309758482> ?p ?o ?g. }

• W4309758482 abstract "Abstract Convergent evolution of SARS-CoV-2 Omicron BA.2, BA.4 and BA.5 lineages has led to the emergence of several new subvariants, including BA.2.75.2, BA.4.6. and BQ.1.1. The subvariants BA.2.75.2 and BQ.1.1 are expected to become predominant in many countries in November 2022. They carry an additional and often redundant set of mutations in the spike, likely responsible for increased transmissibility and immune evasion. Here, we established a viral amplification procedure to easily isolate Omicron strains. We examined their sensitivity to 6 therapeutic monoclonal antibodies (mAbs) and to 72 sera from Pfizer BNT162b2-vaccinated individuals, with or without BA.1/BA.2 or BA.5 breakthrough infection. Ronapreve (Casirivimab and Imdevimab) and Evusheld (Cilgavimab and Tixagevimab) lost any antiviral efficacy against BA.2.75.2 and BQ.1.1, whereas Xevudy (Sotrovimab) remained weakly active. BQ.1.1 was also resistant to Bebtelovimab. Neutralizing titers in triply vaccinated individuals were low to undetectable against BQ.1.1 and BA.2.75.2, 4 months after boosting. A BA.1/BA.2 breakthrough infection increased these titers, which remained about 18-fold lower against BA.2.75.2 and BQ.1.1, than against BA.1. Reciprocally, a BA.5 breakthrough infection increased more efficiently neutralization against BA.5 and BQ.1.1 than against BA.2.75.2. Thus, the evolution trajectory of novel Omicron subvariants facilitated their spread in immunized populations and raises concerns about the efficacy of most currently available mAbs." @default.
• W4309758482 created "2022-11-29" @default.
• W4309758482 creator A5000936651 @default.
• W4309758482 creator A5002144784 @default.
• W4309758482 creator A5008139614 @default.
• W4309758482 creator A5014367426 @default.
• W4309758482 creator A5015197378 @default.
• W4309758482 creator A5031504380 @default.
• W4309758482 creator A5032425111 @default.
• W4309758482 creator A5033376690 @default.
• W4309758482 creator A5034183976 @default.
• W4309758482 creator A5035909668 @default.
• W4309758482 creator A5042248729 @default.
• W4309758482 creator A5044251474 @default.
• W4309758482 creator A5050913628 @default.
• W4309758482 creator A5055017613 @default.
• W4309758482 creator A5055664477 @default.
• W4309758482 creator A5055751945 @default.
• W4309758482 creator A5055755279 @default.
• W4309758482 creator A5065401344 @default.
• W4309758482 creator A5067750454 @default.
• W4309758482 creator A5070919544 @default.
• W4309758482 creator A5073956538 @default.
• W4309758482 creator A5077818599 @default.
• W4309758482 creator A5088376136 @default.
• W4309758482 creator A5089486514 @default.
• W4309758482 creator A5089801954 @default.
• W4309758482 date "2022-11-17" @default.
• W4309758482 modified "2023-10-17" @default.
• W4309758482 title "Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies" @default.
• W4309758482 cites W2077902171 @default.
• W4309758482 cites W2104617152 @default.
• W4309758482 cites W3036391214 @default.
• W4309758482 cites W3083773456 @default.
• W4309758482 cites W3091977890 @default.
• W4309758482 cites W3136616180 @default.
• W4309758482 cites W3139074260 @default.
• W4309758482 cites W3155123963 @default.
• W4309758482 cites W3187723563 @default.
• W4309758482 cites W3206529673 @default.
• W4309758482 cites W4200013604 @default.
• W4309758482 cites W4200170989 @default.
• W4309758482 cites W4205369318 @default.
• W4309758482 cites W4205497912 @default.
• W4309758482 cites W4205520551 @default.
• W4309758482 cites W4206079892 @default.
• W4309758482 cites W4206142017 @default.
• W4309758482 cites W4210665241 @default.
• W4309758482 cites W4220673385 @default.
• W4309758482 cites W4220678484 @default.
• W4309758482 cites W4220908383 @default.
• W4309758482 cites W4220970752 @default.
• W4309758482 cites W4221072241 @default.
• W4309758482 cites W4223581113 @default.
• W4309758482 cites W4225647476 @default.
• W4309758482 cites W4225691034 @default.
• W4309758482 cites W4226004814 @default.
• W4309758482 cites W4226086327 @default.
• W4309758482 cites W4226229183 @default.
• W4309758482 cites W4226525051 @default.
• W4309758482 cites W4280517779 @default.
• W4309758482 cites W4281663532 @default.
• W4309758482 cites W4281754639 @default.
• W4309758482 cites W4282838915 @default.
• W4309758482 cites W4282972656 @default.
• W4309758482 cites W4283026725 @default.
• W4309758482 cites W4283319609 @default.
• W4309758482 cites W4283704819 @default.
• W4309758482 cites W4284678492 @default.
• W4309758482 cites W4285808313 @default.
• W4309758482 cites W4288067813 @default.
• W4309758482 cites W4291189787 @default.
• W4309758482 cites W4295777530 @default.
• W4309758482 cites W4295896122 @default.
• W4309758482 cites W4296186664 @default.
• W4309758482 cites W4296211388 @default.
• W4309758482 cites W4297294440 @default.
• W4309758482 cites W4301394219 @default.
• W4309758482 cites W4302009688 @default.
• W4309758482 cites W4302362524 @default.
• W4309758482 cites W4302759438 @default.
• W4309758482 cites W4306149980 @default.
• W4309758482 cites W4306740332 @default.
• W4309758482 cites W4306839855 @default.
• W4309758482 cites W4306874674 @default.
• W4309758482 cites W4306902076 @default.
• W4309758482 cites W4306964313 @default.
• W4309758482 cites W4307280402 @default.
• W4309758482 cites W4307444588 @default.
• W4309758482 cites W4307850618 @default.
• W4309758482 cites W4307908816 @default.
• W4309758482 cites W4307964984 @default.
• W4309758482 cites W4307965001 @default.
• W4309758482 doi "https://doi.org/10.1101/2022.11.17.516888" @default.
• W4309758482 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36415455" @default.
• W4309758482 hasPublicationYear "2022" @default.
• W4309758482 type Work @default.
• W4309758482 citedByCount "25" @default.
• W4309758482 countsByYear W43097584822022 @default.
• W4309758482 countsByYear W43097584822023 @default.

• next